Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

CHAPEL HILL, N.C., Jan. 12, 2011 /PRNewswire/ -- Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12 in Washington D.C.  

Solithromycin is a clinical-stage fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, non-bacterial pathogens such as Plasmodium falciparum and a variety of bio-defense pathogens including Bacillus anthracis, Yersinia pestis, Burkholderia mallei and Francisella tularensis.  Phase 1 clinical studies with the oral formulation have shown excellent safety and tolerability and a pharmacokinetic profile that will enable once-daily dosing.  The oral formulation is undergoing a Phase 2 clinical trial in patients with community-acquired bacterial pneumonia (CABP).  An intravenous (IV) formulation of solithromycin is undergoing a safety and tolerability evaluation in a Phase 1 single and multiple dose escalation trial in healthy volunteers.  An oral pediatric suspension is also under development.

The presentation, delivered on January 12 by Jennifer Schranz, M.D., vice president of clinical affairs at Cempra Pharmaceuticals, described the potential utility of solithromycin as a bio-defense agent due to its broad antimicrobial spectrum, safety and tolerability, once-daily dosing, high tissue penetration, intracellular accumulation, and compound stability.  Data from mouse models were presented on the activity of once-daily solithromycin compared to an optimal dosing regimen of ciprofloxacin against B. anthracis and gentamicin against F. tularensis.  Solithromycin demonstrated activity comparable to c
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
3. Savient Pharmaceuticals Provides Business Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering Manager ... Orange County, Texas area from future storm surge flooding, such as occurred in Hurricane ... levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental needs ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2
... Mediating RNA interference (RNAi) with , ... been described in the literature (1). Recombinant adenoviruses ... other methods of nucleic acid , ... non-dividing cells, and can be used in animal model systems. , ...
... RNA later Tissue Collection: ... Dissected Tissue and Cells. , ... processing or appropriate storage of the tissue or cell , ... , followed by immediate disruption in ...
... Chris Echeverri, Christoph Sachse, , ... David Brown Ambion, Inc. , ... tool for understanding gene function. ... wherein short double-stranded RNAs called short interfering , ...
Cached Biology Technology:Superior Gene Silencing Using Adenoviral Vectors 2Superior Gene Silencing Using Adenoviral Vectors 3Superior Gene Silencing Using Adenoviral Vectors 4Superior Gene Silencing Using Adenoviral Vectors 5Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation 2Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation 3Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation 4siRNA Design: It's All in the Algorithm 2siRNA Design: It's All in the Algorithm 3siRNA Design: It's All in the Algorithm 4siRNA Design: It's All in the Algorithm 5siRNA Design: It's All in the Algorithm 6siRNA Design: It's All in the Algorithm 7siRNA Design: It's All in the Algorithm 8siRNA Design: It's All in the Algorithm 9siRNA Design: It's All in the Algorithm 10
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... Alberta researchers have published a step by step plan to ... crops by developing plants that produce their own fertilizer. ... the energy required to produce nitrogen fertilizers has pushed the ... year. Good says that while they are necessary for high ...
... 150 years scientists have been trying to explain convergent evolution. ... butterflies from different species evolve to mimic each other,s color ... eat us," while spreading the cost of this lesson. ... UC Irvine assistant professor of ecology & evolutionary biology, has ...
... WHAT: , The ... Center. The event will include more than 16,000 study abstracts on new discoveries ... , , ... have access to special events on the intersection of brain science and society, ...
Cached Biology News:UCI-led butterfly study sheds light on convergent evolution 2Media registration opens for Neuroscience 2011, world's largest meeting on brain science and health 2
Taq DNA polymerase, 10,000U...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Request Info...
Biology Products: